Biodefense R&D: Anticipating Future Threats, Establishing a Strategic Environment

Biosecurity and Bioterrorism

Volumn 1, Issue 3, 2003, Pages 193-202

  Smith, Bradley T ^a   Inglesby, Thomas V ^a   O'toole, Tara ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL WARFARE; CIVIL DEFENSE; HUMAN; MEDICAL RESEARCH; UNITED STATES;

BIOLOGICAL WARFARE; BIOMEDICAL RESEARCH; BIOTERRORISM; CIVIL DEFENSE; HUMANS; UNITED STATES;

EID: 1842434267     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/153871303769201842     Document Type: Article

References (53)

1. National Institutes of Health, National Institute of Allergy and Infectious Diseases. NIAID Biodefense Research Agenda for CDC Category A Agents. February 2002.
2. National Institutes of Health, National Institute of Allergy and Infectious Diseases. NIAID Strategic Plan for Biodefense Research. February 2002.
3. Hopmeier M. The Projected Evolution of Diagnostics, Vaccines, and Therapeutics Against Major Bioagents with Strategic R&D and Supply Actions. Defense Science Board Summer Study, 2000.
4. Facts about Tularemia. Centers for Disease Control and Prevention. http://www.bt.cdc.gov/documentsapp/FactSheet/Tularemia/about.asp. Accessed: July 2, 2003.
5. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285:1059–70.
6. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283:2281–90.
7. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 2002;287:2236–52.
8. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: Medical and public health management. JAMA 2001;285:2763–73.
9. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 2002;287:2391–2405.
10. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281:2127–37.
11. Kwik G, Fitzgerald J, Inglesby TV, et al. Biosecurity: Responsible stewardship of bioscience in an age of catastrophic terrorism. Biosecurity and Bioterrorism 2003;1: 27–35.
12. Enriquez J, Goldberg RA. Transforming life, transforming business: The life-science revolution. Harvard Business Review March/April 2000;96–104.
13. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304–51.
14. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409: 860–921.
15. Price LB, Vogler A, Pearson T, et al. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 2003;47:2362–5.
16. Choe CH, Bouhaouala SS, Brook I, et al. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother 2000;44:1766.
17. Brook I, Elliott TB, Pryor HI, 2nd, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001;18:559–62.
18. Jackson RJ, Ramsay AJ, Christensen CD, et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001;75:1205–10.
19. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001;291:1965–9.
20. Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993;90:8033–7.
21. Edwards DA. Delivery of biological agents by aerosols. AIChE Journal 2002;48:2–6.
22. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002;54:1373–93.
23. Galas DJ, Riggs H. Global science and U.S. security. Science 2003;300:1847.
24. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151–85.
25. Bloom FE. Presidential address. Science as a way of life: Perplexities of a physician-scientist. Science 2003;300: 1680–5.
26. Kohn L, Corrigan J, Donaldson M (eds.). To err is human: Building a safer health system. Washington, DC: National Academies Press; 2000.
27. Adams K, Corrigan J (eds.). Priority areas for nationalaction: Transforming health care quality. Washington, DC: National Academies Press; 2003.
28. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: Institutes of Medicine; 2001.
29. National Intelligence Council. The global infectious disease threat and its implications for the United States. NIE 99-17D. 2000.
30. Koizumi K, Turner PK. Congressional action on research and development in the FY 2002 budget. Washington, DC: American Association for the Advancement of Science; Jan 2002.
31. Koizumi K, Turner PW. Congressional action on research and development in the FY 2003 budget. Washington, DC: American Association for the Advancement of Science R&D Budget and Policy Program; 2003.
32. PhRMA. Annual Report 2001–2002. Washington, DC: Pharmaceutical Research Manufacturers Association; 2002.
33. Biotechnology Industry Statistics. BIO. http://www.bio.org/news/stats.asp. Accessed: July 2, 2003.
34. Sevier ED, Dahms AS. The role of foreign worker scientists in the US biotechnology industry. Nature Biotechnology 2002;20:955–6.
35. The 2002 Global 500. Fortune Magazine. http://www.fortune.com/fortune/global500. Accessed: May 13, 2003.
36. Fauci AS. Biodefence on the research agenda. Nature 2003;421:787.
37. Merton RK. The sociology of science. Chicago, Ill: University of Chicago Press; 1973.
38. Editorial. Obstacles to biodefence. Nature 2002;419:1.
39. Pollack A, Petersen M. Untested companies enlist in U.S. Biodefense, Money and Business. The New York Times, final ed. March 23, 2003, p 1.
40. Dimasi JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297–307.
41. The Patent and Trademark Law Amendments Act, Public Law 96-517. 1980.
42. Rai AK, Eisenberg RS. Bayh-Dole reform and the progress of biomedicine. American Scientist 2003;91:52–59.
43. Statement of Alan Pemberton for the Pharmaceutical Research Manufacturers Association (PhRMA) before the House of Representatives Select Committee on Homeland Security. May 15, 2003.
44. th U.S. Congress, S. 15.
45. th U.S. Congress, S. 666.
46. Bell J. Bio-defense standoff. Baltimore Sun, March 2, 2003, p 1D.
47. Council of the Institute of Medicine. Statement on Vaccine Development. November 5, 2001.
48. Standard Grant Receipt Dates and Review and Award Cycles. National Institutes of Health—Office of Extramural Research. http://grants1.nih.gov/grants/funding/submission schedule.htm. Accessed: July 2, 2003.
49. Committee on the Organizational Structure of the National Institutes of Health, National Research Council. Enhancing the Vitality of the National Institutes of Health: Organizational Change to Meet New Challenges. 2003.
50. Cook-Deegan R. Does NIH need a DARPA? Issues in Science and Technology Winter 1996.
51. Honan M. Homeland official outlines opportunities for tech firms. July 31, 2003. http://govexec.com/news. Accessed: August 7, 2003.
52. Homeland insecurity: Building the expertise to defend America from bioterrorism. Washington, DC: Partnership for Public Service; 2003.
53. Harris G. Bayer's Cipro will be profitable, even on discount deal with U.S. Wall Street Journal. October 26, 2001.